News Related to GnRH Antagonist

Related coverage linked through entity extraction aliases.

Medicus Pharma Reports Phase 2 Results for SkinJect, FDA Clears Teverelix Trial

Mar 05, 2026

Medicus Pharma reported Phase 2 SKNJCT-003 topline data showing 73% clinical clearance and 40% histological clearance at Day 57 in the 200μg cohort. Separately, the FDA cleared the company to begin a Phase 2b dose optimization study for Teverelix in advanced prostate cancer.

GnRH Agonist Leuprolide Linked to Greater Coronary Plaque Growth Than Antagonist Relugolix

Feb 19, 2026

A randomized trial found that men with prostate cancer treated with the GnRH agonist leuprolide experienced significantly more coronary artery plaque progression than those receiving the GnRH antagonist relugolix, suggesting a biological mechanism for cardiovascular risk differences between ADT drug pathways.